Overview
- Investor trading swung sharply Monday as Intellia shares jumped about 25% ahead of the data and then closed down roughly 3% after the release.
- In the 80-patient HAELO study, a single lonvo‑z infusion met the primary and all key secondary endpoints with a mean monthly attack rate of 0.26 versus 2.10 on placebo.
- Safety findings showed only mild to moderate events such as infusion reactions, headache, and fatigue, with no serious adverse events in the treatment arm.
- As of the February 10 cutoff, treated patients stayed off long-term preventive therapy through the six‑month evaluation window, pointing to sustained benefit over that period.
- Intellia has started a rolling FDA application and aims for a potential U.S. launch in the first half of 2027 if approved, with fuller results slated for the EAACI Congress in June and the therapy acting by inactivating KLKB1 to lower bradykinin.